参附联合苦碟子注射液治疗慢性肺心病急性期合并心衰的临床应用价值(1)
 |
| 第1页 |
参见附件(1319KB，2页)。
[摘要] 目的：观察参附联合苦碟子注射液治疗慢性肺心病急性期合并心衰的临床疗效。方法：60例患者随机分为两组，对照组30例给予西医常规治疗；治疗组30例在对照组治疗基础上加用参附注射液和苦碟子注射液静脉滴注。结果：治疗组总有效率(93.3%)与对照组(80.0%)相比，差异有统计学意义(P<0.05)；治疗组在升高动脉血氧分压、降低二氧化碳分压、改善血液流变学指标方面均优于对照组(P<0.05)。结论：参附注射液联合苦碟子注射液对慢性肺心病急性加重期合并心衰的患者疗效显著。
[关键词] 慢性肺心病心力衰竭；参附注射液；苦碟子注射液
[中图分类号] R541.5 [文献标识码] A[文章编号] 1673-7210(2010)11(a)-073-02
Clinical value of Shenfu combined with Kudiezi Injection in treatment of acute exacerbation of chronic pulmonary heart disease complicated by heart failure
WANG Zhoufang, LIU Jihua, MAO Yihui, YU Lan
(The Hospital of Integrated Traditional Chinese and Western Medicine of Deyang City, Deyang 618000, China)
[Abstract] Objective: To observe the efficacy of Shenfu combined with Kudiezi Injection in treatment of acute exacerbation of chronic pulmonary heart disease complicated by heart failure. Methods: 60 patients were randomly divided into control group and treatment group. 30 cases in the control group were treated with conventional Western medical method, 30 cases in the treatment group were added Shenfu and Kudiezi Injection based on conventional Western medical treatment method. Results: Treatment group was better than control group on the total effective rate, blood gas analysis and hemorheology change (P<0.05). Conclusion: Shenfu combined with Kudiezi Injection can improve the efficacy of acute exacerbation of chronic pulmonary heart disease complicated by heart failure.
[Key words] Chronic pulmonary heart disease complicated by heart failure; Shenfu Injection; Kudiezi Injection
慢性肺心病是我国的常见病、多发病、危重病。由于病程迁延，心肺等脏器功能不全，低氧和二氧化碳潴留，水电解质紊乱，体内内环境严重失衡，临床治疗难度大，病死率高。近年来，笔者试用在西医常规治疗基础上静脉滴注参附注射液和苦碟子注射液治疗本病，取得较好疗效，现报道如下：
1 资料与方法
1.1 一般资料
肺心病诊断标准采用1980年全国第3次肺心病专业会议修订标准，肺心病急性发作期以肺心病合并肺部感染为其诊断标准，采用1980年全国第3次肺心病专业会议修订标准[1]。心功能分级按照美国纽约心脏病学会(NYHA)分级方案。本临床研究共纳入60例肺心病急性发作期合并心力衰竭患者，全部来自2007年1月～2010年5月我院内科病房住院患者。根据入院顺序随机分为中西医综合治疗组(治疗组)和西医综合治疗组(对照组)。治疗组中，男18例，女12例；平均年龄(69.74±10.72)岁；病程(12.34±6.81)年；对照组中，男17例，女13例；平均年龄(67.94±8.27)岁；病程(11.88±6.74)年。心功能分级，治疗组Ⅱ级8例，Ⅲ级16例，Ⅳ级6例；对照组Ⅱ级8例，Ⅲ级15例，Ⅳ级7例。两组患者治疗前一般资料比较，无显著性差异(均P>0.05)，具有可比性。
1.2 方法
两组患者均给予低流量吸氧，积极有效的抗感染，祛痰平喘，保持呼吸道的通畅，适当利尿，应用洋地黄，纠正低氧和二氧化碳潴留及电解质紊乱 ......
您现在查看是摘要介绍页，详见PDF附件(1319KB，2页)。